Search results for "Intensive Care Units"

showing 10 items of 251 documents

Serum Lycopene Concentrations and Associations with Clinical Outcomes in a Cohort of Maternal-Infant Dyads.

2018

Oxidative stress has been associated with adverse neonatal outcomes, and many carotenoids, including lycopene, potentially have antioxidant properties. The objective of this analysis was to explore the associations between serum lycopene concentrations, including lycopene isomers, and maternal-newborn outcomes. Maternal and cord blood samples were collected in 180 mother-infant pairs. Serum of total lycopene as well as the cis- and trans-isomers concentrations were measured using HPLC (High Performance Liquid Chromatography). Descriptive statistics were calculated; Spearman coefficients were used to assess correlations between maternal and cord concentrations. The relationship between lycop…

0301 basic medicineAdultCordBirth weightPhysiologyMotherslcsh:TX341-641AntioxidantsArticlelaw.inventionCohort Studies03 medical and health scienceschemistry.chemical_compoundYoung Adult0302 clinical medicinelawPregnancyIntensive Care Units Neonatalcarotenoid; lycopene; pregnancy; neonatal growthmedicineBirth WeightHumansPregnancyRespiratory Distress Syndrome Newborn030219 obstetrics & reproductive medicine030109 nutrition & dieteticsNutrition and DieteticsRespiratory distressbusiness.industryInfant NewbornInfantmedicine.diseaseFetal BloodlycopeneIntensive care unitCarotenoidsLycopenecarotenoid3. Good healthDietOxidative Stresschemistryneonatal growthCord bloodCohortFemalebusinesslcsh:Nutrition. Foods and food supplyFood ScienceNutrients
researchProduct

Candida blood stream infections observed between 2011 and 2016 in a large Italian University Hospital: A time-based retrospective analysis on epidemi…

2019

Candida bloodstream infection (BSI) represents a growing infective problem frequently associated to biofilm production due to the utilization of intravascular devices. Candida species distribution (n = 612 strains), their biofilm production and hospital antifungal drug consumption were evaluated in different wards of a tertiary care academic hospital in Italy during the years 2011–2016. In the considered time window, an increasing number of Candida BSI (p = 0.005) and of biofilm producing strains were observed (p<0.0001). Although C. albicans was the species more frequently isolated in BSI with a major biofilm production, an increased involvement of non-albicans species was reported, partic…

0301 basic medicineAntifungal AgentsTime FactorsAntifungal drugYeast and Fungal ModelsPathology and Laboratory Medicinelaw.inventionHospitals Universitychemistry.chemical_compound0302 clinical medicinelawAmphotericin BMedicine and Health Sciences030212 general & internal medicineAmphotericinFluconazoleCandidaFungal PathogensPrincipal Component AnalysisMultidisciplinaryAntimicrobialsQCandidiasisREukaryotaDrugsIntensive care unitHospitalsCorpus albicansIntensive Care UnitsExperimental Organism SystemsItalyMedical MicrobiologyEngineering and TechnologyMedicinePathogensResearch ArticleBiotechnologymedicine.drugCandida Candida bloodstream infection biofilm antifungal agents drug susceptibilityCathetersScience030106 microbiologyBioengineeringMycologyMicrobial Sensitivity TestsResearch and Analysis MethodsMicrobiologyMicrobiology03 medical and health sciencesMicrobial ControlmedicineCandida AlbicansHumansMicrobial PathogensRetrospective StudiesPharmacologyVoriconazoleAntifungalsbusiness.industryOrganismsFungiBiofilmBiology and Life SciencesYeastHealth CarechemistryHealth Care FacilitiesBiofilmsAnimal StudiesMedical Devices and EquipmentAntimicrobial ResistanceCaspofunginbusinessFluconazolePLOS ONE
researchProduct

Genotyping and Antifungal Susceptibility of Dipodascus capitatus Isolated in a Neonatal Intensive Care Unit of a Sicilian Hospital

2017

In August 2015, Dipodascus capitatus was isolated from two patients admitted to the neonatal intensive care unit. Nosocomial acquisition of the fungus was suspected and epidemiological studies were undertaken. The patients were simultaneously hospitalized, and the comparison of the two isolates by two independent molecular typing methods have confirmed clonal dissemination of a single strain of D. capitatus. Antimicrobial susceptibility testing was useful for identifying the appropriated antifungal therapy in micafungin. To our knowledge these are the first described cases of neonatal D. capitatus infection and also the first report of successful treatment by micafungin.

0301 basic medicineAntifungalGenotypingPediatricsmedicine.medical_specialtyClonal disseminationNeonatal intensive care unitmedicine.drug_class030106 microbiologyDipodascus03 medical and health sciencesEpidemiologymedicineDipodascus capitatuAntifungal SusceptibilityDipodascus capitatusGenotypingBiochemistry Genetics and Molecular Biology (all)biologyMedicine (all)MicafunginAntifungal Susceptibility; Dipodascus capitatus; Genotyping; Nosocomial Acquisition; Cross Infection; Dipodascus; Female; Genotype; Hospitals; Humans; Infant; Infant Newborn; Intensive Care Units Neonatal; Male; Mycoses; Sicily; Medicine (all); Biochemistry Genetics and Molecular Biology (all)biology.organism_classificationNosocomial AcquisitionAntifungal Susceptibility; Dipodascus capitatus; Genotyping; Nosocomial Acquisition; Medicine (all); Biochemistry Genetics and Molecular Biology (all)medicine.drug
researchProduct

High prevalence and moderate diversity of Pseudomonas aeruginosa in the U-bends of high-risk units in hospital

2017

The presence of P. aeruginosa in water supply is clearly identified as a risk factor for P. aeruginosa infection in critical care units, even if routes of transmission are often unclear and remain a matter of debate. We determined here the frequency of U-bends contaminated with P. aeruginosa in high-risk units and described the population structure of this opportunistic pathogen in a non-outbreak situation. Eighty-seven U-bends from sinks of rooms in five wards were sampled 3 times and P. aeruginosa was detected in 121 of the 261 (46.4%) U-bend samples. We genotyped 123 P. aeruginosa isolates with pulsed-field gel electrophoresis and multilocus sequence typing and found 41 pulsotypes distri…

0301 basic medicineGenotype030106 microbiologyPopulation structure030501 epidemiologyBiology[ SDV.MP.BAC ] Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriologymedicine.disease_causeMicrobiology03 medical and health sciencesOpportunistic pathogenDrug Resistance BacterialmedicineWater PollutantsCladeComputingMilieux_MISCELLANEOUSHigh prevalencePseudomonas aeruginosaDrainage SanitaryPublic Health Environmental and Occupational HealthGenetic Variation[ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologieSequence types[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology6. Clean waterHospitalsAnti-Bacterial AgentsIntensive Care UnitsPseudomonas aeruginosaMultilocus sequence typing[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie0305 other medical scienceWater MicrobiologyEnvironmental Monitoring
researchProduct

Rapid detection of carbapenem resistance: Targeting a zero level of inadequate empiric antibiotic exposure

2016

Resistance to carbapenems is an increasingly encountered phenomenon in the ICU, complicating empiric and targeted antimicrobial therapy. Infections due to carbapenem-resistant microorganisms are characterized by high morbidity and mortality [1, 2]. Recently, there has been an increasing interest in rapid detection techniques, based on real time on-demand easy-to-use PCR, to detect genes responsible for carbapenem resistance. One of these techniques is the Cepheid Xpert Carba-R assay, which is able to detect and differentiate five of the most frequent genes associated with non-susceptibility to carbapenems in Gram-negative bacteria (bla KPC, bla VIM, bla OXA-48, bla IMP-1, bla NDM). The diag…

0301 basic medicineGram-negative bacteriaLetterCarbapenem resistanceMultidrug-resistant bacteria030106 microbiologyDrug ResistanceDrug resistanceCritical Care and Intensive Care MedicineMicrobiologylaw.invention03 medical and health sciences0302 clinical medicinelawGram-Negative Bacteriapolycyclic compoundsMedicineInfection controlHumansCarbapenem resistance; Multidrug-resistant bacteria; Polymerase chain reaction; Critical Care and Intensive Care MedicinePolymerase chain reactionCarbapenem resistancebiologybusiness.industryOutbreak030208 emergency & critical care medicinebiochemical phenomena metabolism and nutritionbacterial infections and mycosesbiology.organism_classificationAntimicrobialPolymerase chain reactionIntensive Care UnitsCarbapenemsEtiologyCarbapenem resistance; Multidrug-resistant bacteria; Polymerase chain reactionbusiness
researchProduct

Use of Cepheid Xpert Carba-R® for Rapid Detection of Carbapenemase-Producing Bacteria in Abdominal Septic Patients Admitted to Intensive Care Unit.

2016

Abstract Early institution of effective antibiotic therapy and source control are pivotal to improve survival of abdominal septic patients. Xpert® Carba-R is a real time polymerase chain reaction assay for rapid detection and differentiation of five genes (blaKPC, blaVIM, blaOXA-48, blaIMP-1, blaNDM) responsible for carbapenem resistance. We performed an observational study investigating the clinical usefulness and applicability of Xpert® Carba-R to detect carbapenem resistance in abdominal septic patients admitted to intensive care unit. We compared the results of Xpert® Carba-R with standard microbiological culture. We collected a set of two rectal/stomia swabs and two swabs from abdomina…

0301 basic medicineMaleMicrobiological cultureAntibioticslcsh:MedicineArtificial Gene Amplification and ExtensionPathology and Laboratory MedicinePolymerase Chain Reactionlaw.inventionKlebsiella Pneumoniae0302 clinical medicinelawAntibioticsKlebsiellaEpidemiologymultidrug resistance sepsis intensive care unitAbdomenMedicine and Health SciencesMedicine030212 general & internal medicinelcsh:ScienceMultidisciplinaryAntimicrobialsCepheid Xpert Carba-R®DrugsMicrobial CulturesMiddle AgedIntensive care unitHospitalsBacterial PathogensIntensive Care UnitsAbdominal SurgeryMedical MicrobiologyFemaleBiological CulturesPathogensResearch ArticleDNA Bacterialmedicine.medical_specialtymedicine.drug_class030106 microbiologySurgical and Invasive Medical ProceduresResearch and Analysis MethodsReal-Time Polymerase Chain ReactionRapid detectionMicrobiologySensitivity and Specificitybeta-Lactamases03 medical and health sciencesAntibiotic resistanceBacterial ProteinsEnterobacteriaceaeDiagnostic MedicineInternal medicineIntensive careMicrobial ControlSepsisDrug Resistance BacterialHumansMED/41 - ANESTESIOLOGIAMolecular Biology TechniquesMicrobial PathogensMolecular BiologyAgedPharmacologyBacteriabusiness.industrylcsh:ROrganismsRectumBiology and Life SciencesSurgeryHealth CareCarbapenemsHealth Care FacilitiesAntibiotic Resistancelcsh:QAntimicrobial ResistanceReagent Kits DiagnosticbusinessAbdominal surgery
researchProduct

Intersociety policy statement on the use of whole-exome sequencing in the critically ill newborn infant.

2017

Abstract The rapid advancement of next-generation sequencing (NGS) technology and the decrease in costs for whole-exome sequencing (WES) and whole-genome sequening (WGS), has prompted its clinical application in several fields of medicine. Currently, there are no specific guidelines for the use of NGS in the field of neonatal medicine and in the diagnosis of genetic diseases in critically ill newborn infants. As a consequence, NGS may be underused with reduced diagnostic success rate, or overused, with increased costs for the healthcare system. Most genetic diseases may be already expressed during the neonatal age, but their identification may be complicated by nonspecific presentation, esp…

0301 basic medicineMaleNeonatal intensive care unitDiseaseReview030105 genetics & heredityPediatricsWhole Exome SequencingNeonateNeonatalOutcome Assessment Health CareDiagnosisPolicy MakingExome sequencingSanger sequencingGenomelcsh:RJ1-570Perinatology and Child HealthSettore MED/38Intensive Care UnitsItalyWhole-exome sequencingPractice Guidelines as TopicsymbolsWESFemaleHumanDiagnosiNICUmedicine.medical_specialtyMendelian03 medical and health sciencessymbols.namesakeOutcome Assessment (Health Care)Neonatal ScreeningNeonatal intensive care unitGeneticIntensive Care Units NeonatalExome SequencingmedicineDiagnosis; Genetic; Genome; Mendelian; Neonatal intensive care unit; Neonate; NICU; WES; WGS; Whole-exome sequencing; Pediatrics Perinatology and Child HealthHumansGenetic TestingIntensive care medicineSettore MED/06 - ONCOLOGIA MEDICAGenetic heterogeneityCritically illbusiness.industryGenome HumanInfant NewbornInfantlcsh:PediatricsNewbornInfant newborn030104 developmental biologyDiagnosis; Genetic; Genome; Mendelian; NICU; Neonatal intensive care unit; Neonate; WES; WGS; Whole-exome sequencing; Female; Genetic Testing; Genome Human; Humans; Infant; Infant Newborn; Intensive Care Units Neonatal; Italy; Male; Neonatal Screening; Outcome Assessment (Health Care); Policy Making; Whole Exome Sequencing; Practice Guidelines as TopicPediatrics Perinatology and Child HealthDifferential diagnosisbusinessWGS
researchProduct

Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic an…

2016

Objectives: We utilized the database of the Defining Antibiotic Levels in Intensive care unit patients (DALI) study to statistically compare the pharmacokinetic/pharmacodynamic and clinical outcomes between prolonged- infusion and intermittent-bolus dosing of piperacillin/tazobactam and meropenem in critically ill patients using inclusion criteria similar to those used in previous prospective studies. Methods: This was a post hoc analysis of a prospective, multicentre pharmacokinetic point-prevalence study (DALI), which recruited a large cohort of critically ill patients from 68 ICUs across 10 countries. Results: Of the 211 patients receiving piperacillin/tazobactam and meropenem in the DAL…

0301 basic medicineMalePenicillanic Acidintensive care unitlaw.inventionthienamycin derivative abdominal infection[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseaseslawcentral nervous system infectioncreatinine clearancePharmacology (medical)Infusions IntravenouProspective StudiesInfusions IntravenousProspective cohort studyTazobactam Drug CombinationAged; Anti-Bacterial Agents; Blood Chemical Analysis; Critical Illness; Female; Humans; Infusions Intravenous; Intensive Care Units; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin Tazobactam Drug Combination; Prospective Studies; Thienamycins; Treatment Outcome; Pharmacology; Microbiology (medical); Pharmacology (medical); Infectious Diseasescritical illneMicrobial Sensitivity TestadultRespiratory infectionclinical trialMiddle Agedcontinuous infusionanalogs and derivativeIntensive care unit3. Good healthAnti-Bacterial Agentsantiinfective agentintravenous drug administrationIntensive Care Units[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyTreatment OutcomeInfectious DiseasesPiperacillin/tazobactammulticenter study (topic)SOFA scoreFemaletreatment outcome AgedIntravenousprospective studyHumanmedicine.drugsurvival rateMicrobiology (medical)medicine.medical_specialtyInfusionspost hoc analysirespiratory tract infectionCritical IllnessAged; Anti-Bacterial Agents; Blood Chemical Analysis; Critical Illness; Female; Humans; Infusions Intravenous; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Prospective Studies; Thienamycins; Treatment Outcome; Pharmacology; Pharmacology (medical); Infectious Diseases030106 microbiologybloodstream infectionMicrobial Sensitivity Testsminimum inhibitory concentrationpiperacillin plus tazobactamMeropenemTazobactamArticle03 medical and health sciencescritically ill patientInternal medicineAnti-Bacterial AgentmedicineSequential Organ Failure Assessment ScoreHumansThienamycinsurvival timeblood analysiAgedPiperacillinPharmacologybusiness.industryBlood Chemical AnalysiMeropenemmajor clinical studySurgeryProspective Studiemulticenter studyPharmacology; Pharmacology (medical); Infectious Diseases[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologyThienamycinspiperacillin tazobactam drug combinationurinary tract infectionbusinessBlood Chemical AnalysisPiperacillin
researchProduct

Genetic justification of severe COVID-19 using a rigorous algorithm

2021

Recent studies suggest excessive complement activation in severe coronavirus disease-19 (COVID-19). The latter shares common characteristics with complement-mediated thrombotic microangiopathy (TMA). We hypothesized that genetic susceptibility would be evident in patients with severe COVID-19 (similar to TMA) and associated with disease severity. We analyzed genetic and clinical data from 97 patients hospitalized for COVID-19. Through targeted next-generation-sequencing we found an ADAMTS13 variant in 49 patients, along with two risk factor variants (C3, 21 patients; CFH,34 patients). 31 (32%) patients had a combination of these, which was independently associated with ICU hospitalization (…

0301 basic medicineMaleThrombomodulinSeverity of Illness Index0302 clinical medicineRisk FactorsImmunology and AllergyMedicineComplement ActivationRigorous algorithmmedicine.diagnostic_testHigh-Throughput Nucleotide SequencingComplement C3EculizumabEculizumabMiddle AgedHospitalizationSettore ICAR/09 - Tecnica Delle CostruzioniIntensive Care UnitsFactor HComplement Factor HFemaleAlgorithmsmedicine.drugmedicine.medical_specialtyThrombotic microangiopathyCritical CareImmunologyComplementADAMTS13 Protein03 medical and health sciencesInternal medicineFull Length ArticleSeverity of illnessGenetic predispositionGenetic susceptibilityHumansGenetic Predisposition to DiseaseGenetic TestingRisk factorGenetic testingAgedbusiness.industryThrombotic MicroangiopathiesCOVID-19medicine.diseaseComplement system030104 developmental biologySARS-CoV2business030215 immunologyClinical Immunology (Orlando, Fla.)
researchProduct

Predicting invasive fungal disease due to Candida species in non-neutropenic, critically ill, adult patients in United Kingdom critical care units.

2016

BACKGROUND: Given the predominance of invasive fungal disease (IFD) amongst the non-immunocompromised adult critically ill population, the potential benefit of antifungal prophylaxis and the lack of generalisable tools to identify high risk patients, the aim of the current study was to describe the epidemiology of IFD in UK critical care units, and to develop and validate a clinical risk prediction tool to identify non-neutropenic, critically ill adult patients at high risk of IFD who would benefit from antifungal prophylaxis. METHODS: Data on risk factors for, and outcomes from, IFD were collected for consecutive admissions to adult, general critical care units in the UK participating in t…

0301 basic medicineMalemedicine.medical_specialtyAntifungal AgentsLetterCritical Illness030106 microbiologyPopulationRisk Assessmentlaw.invention03 medical and health sciences0302 clinical medicineMedical microbiologylawRisk FactorsInvasive fungal infectionsSepsisEpidemiologyCandida albicansmedicineHumansCandidiasis InvasiveeducationIntensive care medicineAgedCandidaCandida sppeducation.field_of_studyAdult patientsCritically illbusiness.industryIncidence (epidemiology)IncidenceCandidiasisCandidemia030208 emergency & critical care medicineAntibiotic ProphylaxisMiddle AgedIntensive care unitUnited KingdomIntensive Care UnitsInfectious DiseasesInvasive fungal diseaseFemalebusinessBMC infectious diseases
researchProduct